What is the current stock price of Altimmune, Inc. (ALT)?

As of the latest market data, Altimmune, Inc. (ALT) is trading at $3.24. The stock has seen a loss of -4.14% today.

Does Altimmune, Inc. (ALT) pay a dividend?

Based on current data, Altimmune, Inc. does not have a confirmed active dividend policy.

What is the market cap of Altimmune, Inc.?

The current market capitalization of Altimmune, Inc. (ALT) is approximately unavailable.

ALT

Altimmune, Inc.·Healthcare

3.24

4.142%(−0.14)

Market Closed

3.57

10.185%(+0.33)

After Hours

Last Updated: — ET

52W L: $2.8752W H: $7.73

ALT NEWS

defenseworld.net

6d ago

Altimmune (NASDAQ:ALT) versus TNF Pharmaceuticals (NASDAQ:TNFA) Head-To-Head Comparison

TNF Pharmaceuticals (NASDAQ: TNFA - Get Free Report) and Altimmune (NASDAQ: ALT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Risk and Volatility TNF Pharmaceuticals has a beta

zacks.com

Mar 26

ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms

Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.

zacks.com

Mar 26

Altimmune Stock: Neutral Outlook With Big 2026 Catalysts

Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.

zacks.com

Mar 26

ALT Pemvidutide Explained: What Makes It Different in MASH

Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.

seekingalpha.com

Mar 12

Altimmune: The High Cost Of Going Solo (Rating Downgrade)

Altimmune, Inc. appears undervalued on risk-adjusted NPV but faces severe funding and competitive headwinds. Pemvidutide's Phase 3 MASH program is ambitious, requiring significant capital, and now includes titration, impacting its tolerability edge. The pipeline's AUD and ALD indications have negative risk-adjusted NPVs and further strain ALT's financial position.

seekingalpha.com

Mar 12

Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2017-05-26

Beta

0.34

Websitealtimmune.com↗